// App-Quantinova.ai

: Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Researchers

Presenter

  • Paul J Bröckelmann

Principal Investigators

  • Ina Bühnen

  • Julia Meissner

  • Karolin Trautmann-Grill

  • Peter Herhaus

  • Teresa V Halbsguth

  • Valdete Schaub

  • Andrea Kerkhoff

  • Stephan Mathas

  • Matthias Bormann

  • Andreas Dickhut

  • Helen Kaul

  • Michael Fuchs

  • Carsten Kobe

  • Christian Baues

  • Peter Borchmann

  • Andreas Engert

  • Bastian von Tresckow

Medical Centers

  • Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt/M., Franfkurt, Germany

  • Klinikum Fulda, Fulda, Germany

  • Internal Medicine III, School of Medicine, Klinikum rechts der Isar, Technische Universität München, München, Germany

  • Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany

  • German Hodgkin Study Group (GHSG), Cologne, Germany, Cologne, Germany

  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

  • Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany

  • Klinikum Bremen Mitte, Bremen, Germany

  • German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, Faculty of Medicine and University of Cologne, Cologne, Germany

  • Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

  • Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University of Cologne, Faculty of Medicine, Cologne, Germany

  • German Hodgkin Study Group (GHSG), Germany and Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany, University Hospital of Cologne, Cologne, Germany

  • Medizinische Klinik II, Universitätsklinikum Tübingen, Tübingen, Germany

  • Department of Radiooncology and Cyberknife Center, Faculty of Medicine and University of Cologne, Cologne, Germany

  • Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany

  • Medicine V, University of Heidelberg, Heidelberg, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Feasibility

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved